Article
Intraperitoneal injection of the pancreatic peptide amylin potently reduces behavioral impairment and brain amyloid pathology in murine models of Alzheimer's disease.
Molecular psychiatry - 1 Feb 2015
Zhu H, Wang X, Wallack M, Li H, Carreras I, Dedeoglu A, Hur J-Y, Zheng H, Li H, Fine R, Mwamburi M, Sun X, Kowall N, Stern R A, Qiu W Q
Abstract excerpt
Amylin, a pancreatic peptide, and amyloid-beta peptides (Aβ), a major component of Alzheimer's disease (AD) brain, share similar β-sheet secondary structures, but it is not known whether pancreatic amylin affects amyloid pathogenesis in the AD brain. Using AD mouse models, we investigated the effects of amylin and its clinical analog, pramlintide, on AD pathogenesis. Surprisingly, chronic intraperitoneal (i.p.)...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.